How to take, the dosage
Daily by p/k or as short intravenous infusions (30-minute infusions) on 5% dextrose solution (see Dilution Instructions) until neutrophil counts pass the expected minimum (nadir) and return to the normal range. The choice of route of administration depends on the specific clinical situation. The p/k route of administration is preferred.
The safety and efficacy of administration of Neupogen® on the same day as myelosuppressive cytotoxic chemotherapy have not been established. Because of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, administration of Neupogen® 24 hours before or after administration of these drugs is not recommended.
Treatment with Neupogen should only be performed under the supervision of an oncologist or hematologist experienced in the use of G-CSF, with the necessary diagnostic capabilities. Cell mobilization and apheresis procedures should be performed at an oncology or hematology center experienced in this field and the ability to adequately monitor hematopoietic progenitor cells.
a) Malignant Cell Growth
The safety and effectiveness of Neupogen® in patients with myelodysplastic syndrome and chronic myeloleukemia are not established, so it is not indicated for these diseases. Particular attention should be paid to the differential diagnosis between acute myeloleukemia and the blast crisis of chronic myeloleukemia.
Human G-CSF can stimulate growth of myeloid cells in vitro. Similar effects may be observed in vitro for some non-myeloid cells.
b) Patients receiving cytotoxic chemotherapy
Clear colorless or slightly yellowish liquid, odorless or faintly odorless.
No cases of overdose have been reported.
Category C drug.
2 years. Do not use after the expiration date stated on the package.
|Conditions of storage|
At a temperature of 2-8 °C. .
Amgen Europe B.V., Netherlands
solution for injection
Amgen Europe B.V.
Buy Neupogen syringe-tubes, units 0.5 ml with delivery to USA, UK, Europe and over 120 other countries.